

09/402936
PATENT COOPERATION TREATY

PCT

16 X 1

1636

INTERNATIONAL PRELIMINARY EXAMINATION REPORT REC'D 27 JUN 2000

(PCT Article 36 and Rule 70)

WIPO


PCT

Applicant's or agent's file reference 082584/0104	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US98/07388	International filing date (day/month/year) 14 APRIL 1998	Priority date (day/month/year) 14 APRIL 1997
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant AMERICAN CYANAMID COMPANY		

RECEIVED

AUG 03 2000

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>27</u> sheets.</p>		TECH CENTER 1600/2900
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		

Date of submission of the demand 16 NOVEMBER 1998	Date of completion of this report 30 JUNE 1999
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile N . (703) 305-3230	Authorized officer DAVID GUZO  Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07388

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 6, 7.1, 29, 69.1, 172.3, 235.1, 320.1, 325, 348, 352, 254.11; 536/23.1, 23.5; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Dialog, Biosis, Medline, Biotech, Biosci

Search terms: juvenile hormone, juvenile hormone receptor, basic helix loop helix, methoprene tolerant, insecticides

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YAO et al. Drosophila Ultraspiracle Modulates Ecdysone Receptor Function via Heterodimer Formation. Cell. 02 October 1992, Vol. 71, pages 63-72, especially 69-70.	1-51
A	SHEMSHEDINI et al. Resistance to Juvenile Hormone and an Insect Growth Regulator in Drosophila is Associated with an Altered Cytosolic Juvenile Hormone-Binding Protein. Proceedings of the National Academy of Sciences. March 1990, Vol. 87, pages 2072-2076, especially page 2075.	1-51



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 MAY 1998

Date of mailing of the international search report

06 JUL 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID GUZO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/07388

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KELLEY et al. Restriction of P-Element Insertions at the Notch Locus of <i>Drosophila Melanogaster</i> . <i>Molecular and Cellular Biology</i> . April 1987, Vol. 7, No. 4, pages 1545-1548, especially page 1546.	1-51

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/07388

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C12N 1/15, 5/10, 15/11, 15/63, 15/81, 15/86; C07H 21/04; C07K 14/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/5, 6, 7.1, 29, 69.1, 172.3, 235.1, 320.1, 325, 348, 352, 254.11; 536/23.1, 23.5; 530/350

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

14 December 1998 (14.12.98)

International application No.

PCT/US98/07388

Applicant's or agent's file reference

082584/0104

International filing date (day/month/year)

14 April 1998 (14.04.98)

Priority date (day/month/year)

14 April 1997 (14.04.97)

Applicant

WILSON, Thomas, G. et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

16 November 1998 (16.11.98)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Athina Nickitas-Etienne

Telephone No.: (41-22) 338.83.38

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/07388

I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):*

☐ the international application as originally filed.

☒ the description, pages (See Attached), as originally filed.

pages _____, filed with the demand.

pages _____, filed with the letter of _____.

pages _____, filed with the letter of _____.

☒ the claims, Nos. (See Attached), as originally filed.

Nos. _____, as amended under Article 19.

Nos. _____, filed with the demand.

Nos. _____, filed with the letter of _____.

Nos. _____, filed with the letter of _____.

☒ the drawings, sheets/fig (See Attached), as originally filed.

sheets/fig _____, filed with the demand.

sheets/fig _____, filed with the letter of _____.

sheets/fig _____, filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

☒ the description, pages NONE.

☒ the claims, Nos. NONE.

☒ the drawings, sheets/fig NONE.

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US98/07388

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)

Claims 1-51

YES

Claims NONE

NO

Inventive Step (IS)

Claims 1-51

YES

Claims NONE

NO

Industrial Applicability (IA)

Claims 1-51

YES

Claims NONE

NO

2. CITATIONS AND EXPLANATIONS

Claims 1-51 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the isolated bHLH-PAS polypeptides, nucleic acid sequences encoding said polypeptides, expression vectors containing said nucleic acids, host cells containing said expression vectors, methods of screening compounds that specifically bind with a bHLH-PAS/JHR polypeptide and methods of detecting JH-resistant individuals in a population. The invention has industrial applicability in that the invention provides for an efficient method for testing insecticides targeted for the JH system in insects.

NEW CITATIONS

NONE

RECEIVED

AUG 23 2000

TECH CENTER 1600/2900

Suppl mental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): C12N 1/15, 5/10, 15/11, 15/63, 15/81, 15/86; C07H 21/04; C07K 14/00 and US Cl.: 435/5, 6, 7.1, 29, 69.1, 172.3, 235.1, 320.1, 325, 348, 352, 254.11; 536/23.1, 23.5; 530/350

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
pages, 2, 3, 5-65 and 68-69, as originally filed.
pages, NONE, filed with the demand.
and additional amendments:

Pages 1, 4, 66 and 67, and sequence listing pages 1-22, filed with the letter of 11 May 1999.

This report has been drawn on the basis of the claims,
numbers, 1-35 and 44-51, as originally filed.
numbers, NONE, as amended under Article 19.
numbers, NONE, filed with the demand.
and additional amendments:

Claims 36-43, filed with the letter of 11 May 1999.

This report has been drawn on the basis of the drawings,
sheets, 1-10, as originally filed.
sheets, NONE, filed with the demand.
and additional amendments:
NONE

Inventors: Thomas G. Wilson
Julia N. Heinrich

RECOMBINANT bHLH-PAS/JHR POLYPEPTIDE AND ITS USE
TO SCREEN POTENTIAL INSECTICIDES

5 BACKGROUND OF THE INVENTION

The present invention relates to a cloned "basic helix loop helix -PER-ARNT-AhR-SIM" (bHLH-PAS) protein that is a juvenile hormone receptor (JHR), bHLH-PAS/JHR. In particular, this invention is directed to a bHLH-PAS/JHR gene isolated from *Drosophila*, termed the methoprene-tolerant (*met*) gene (*Met*-JHR). The present invention also is directed to *in vitro* and *in vivo* methods for screening insecticides using recombinant bHLH-PAS/JHRs. The present invention is further directed to methods for isolating polynucleotides encoding bHLH-PAS/JHRs from various insect species.

Worldwide insect damage to food and fiber costs billions of dollars annually. Although chemical insecticides are still the primary means of insect control, the use of chemicals has several drawbacks including high cost of discovery, potential environmental damage, and negative public opinion. One promising group of insecticides consists of analogues of insect hormones, such as juvenile hormone. Since vertebrates do not make juvenile hormone (JH), insecticides targeted to the JH system are highly toxic to certain insects, and have shown an extraordinary degree of environmental safety.

Juvenile hormones comprise a family of hormones that are secreted by the corpus allatum, and that play a role in a variety of critical functions in insects, including development, reproduction, and morphological differentiation. Riddiford, "Hormone Action at the

molecules. A genomic polynucleotide comprising the Met gene is the St-H fragment in Figure 1. This fragment is 6.234 Kb, and its sequence is shown in Figure 2 (SEQ ID NO:1). Within this 6.234 Kb segment, there is a DNA
5 sequence of 3.011 Kb, which includes an open reading frame that is divided by one intron of 69 nucleotides (bases 1520 to 1588). This 3.011 Kb sequence is the genomic Met-JHR DNA sequence. Figure 3 (SEQ ID NO:2).

The Met-JHR open reading frame lacking the intron
10 codes for a protein of 716 amino acids and a having a molecular weight of about 78,720 daltons.

The nucleotide sequences of the genomic and cDNA Met-JHR differ, reflecting polymorphism. In Figure 3, SEQ ID NO:3 represents a Met-JHR cDNA sequence, which begins at
15 nucleotide 4 of the genomic sequence. There is one "polymorphic" difference between the genomic and cDNA nucleotide sequences that results in a change at the amino acid level. The nucleotide at position 1043 (genomic)/1039 (cDNA) may be C or T, which results in
20 different deduced amino acids, R and W, respectively.

In the sequence of the genomic DNA, there is one ambiguity that results in different deduced amino acids. Base number 875 in the genomic DNA is designated "R," which signifies that the nucleotide may be the purine C
25 or G. This results in two possible corresponding deduced amino acid sequences, G (Gly) or R (Arg) respectively. In the sequence of the cDNA, there is one ambiguity that results in a different deduced amino acids. Base number 526 in the genomic DNA is designated "M," which signifies
30 that the nucleotide may be the purine A or C. This results in two possible corresponding deduced amino acid sequences, T (Thr) or P (Pro) respectively.

As used herein, the term "juvenile hormone receptor" (JHR) is used to mean a polypeptide that is
35 involved in binding JHIII. As used herein, a polypeptide that is "involved in binding" JHIII includes a

transcript with the genomic nucleotide sequence. The probable transcription start site for this transcript begins 220 bp upstream from the start codon and the probably transcript ends 912 bp from the stop codon.

5 A comparison of the cDNA to the genomic sequence showed that the genomic ORF is 2.22 Kb and the cDNA ORF is 2.151 Kb. The difference between the two sequences is a 69 nucleotide intron, which corresponds to 23 codons, and does not change the open reading frame of the genomic
10 and cDNA. The presence of the intron provides evidence for the possibility of alternatively spliced variants of Met-JHR and hence multiple isoform proteins of Met-JHR.

The longest single open reading frame in the cDNA in Figure 3 (SEQ ID NO:3) comprises a single open reading
15 frame (ORF). The DNA sequence (CAAAATGGCA) (SEQ ID NO:13) surrounding this ATG of the ORF is in good agreement with a *Drosophila* translation start site consensus sequence. Cavener Nucl. Acid. Res. 15:1353 (1987).

20 The first genomic exon is from position 224 to position 1543 (1296 bases). This is followed by a 69 bp intron, and a second exon, which extends from position 1589 to 2443 (855 bases). The remainder of the Met-JHR gene is from 2443 to 3011 (568 bases). The total length
25 of the nucleotide sequence provided for the genomic DNA is 3011 nucleotides (SEQ ID NO:2), and that of the cDNA is 3282 nucleotides (SEQ ID NO:3).

Comparison of the Met-JHR ORF and with sequences deposited in the Genbank database showed three regions of
30 homology to members of a family of transcriptional activators known as the basic helix-loop-helix-Per-Arnt-Sim (bhlh-PAS) proteins. See Figure 6. Three vertebrate members of this family include the aromatic hydrocarbon receptor nuclear translocator (ARNT), muscle and brain
35 ARNT-like protein 1 (BMAL-1), and the aromatic hydrocarbon receptor (AHR). Three *Drosophila* family

members include ARNT (DARNT), Trachealess (*Trh*) and Single-minded (*Sim*).

5 The ARNT and AHR proteins are involved as heterodimeric partners in binding a variety of environmental toxicants, including dioxin, and subsequently activating a variety of genes important in the degradation of these chemicals, such as the cytochrome P450 genes. Figure 6 indicates that Met-JHR is neither DARNT nor AHR. However, Met-JHR shares
10 considerable homology to human AHR in the ligand binding region of AHR, which is amino acids 200-400 of AHR. Rowlands et al. *Crit. Rev. Toxicol.* 27:109 (1997). Another feature apparent from visual inspection of the Met-JHR sequence is that Met-JHR, like human ARH (HARH),
15 has a high concentration of serine and threonine residues at its carboxyl terminus. This is the motif of a S/P/T transactivation domain, as noted above. In ARH, this domain has been shown to be a functional TAD.

These features support the hypothesis that the
20 mechanism of action of Met-JHR is similar to AHR, i.e., Met-JHR binds the JH ligand. In addition, the Met-JHR may heterodimerize to DARNT or a DARNT-like protein in order to bind a JH response element and mediate JH action. The bHLH domain has been shown to be involved in
25 dimerization and DNA binding. Rowlands et al. *Critical Reviews in Toxicology*, 27: 109 (1997).

Met-JHR also contains the "LXXLL" (SEQ ID NO:14) motif which likens Met to steroid receptor co-activators. Although this motif is found in many proteins, it plays
30 a significant role in proteins that interact with co-activators of steroid receptors. LXXLL (SEQ ID NO:14) also has been found in a bHLH-PAS protein that is a cofactor (ACTR) [Chen et al. *Cell* 90:569 (1997)] that is amplified in breast cancer-1 (AIBC). Anzick et al.
35 *Science* 277:965 (1997). This bHLH-PAS protein (ACTR/AIBC) interacts with a steroid

and the DNA binding region of a second polypeptide, (2) DNA encoding a bHLH-PAS polypeptide and the activation domain of said second polypeptide, and (3) a reporter gene under the control of a minimal promoter driven by the response element for said second polypeptide;

(b) incubating a test compound with said host cell; and

(c) detecting the binding of the test compound with said bHLH-PAS polypeptide by monitoring expression of the reporter gene.

37. A method according to claim 32, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

38. A method according to claim 33, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

39. A method according to claim 34, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

40. A method according to claim 35, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

41. A method according to claim 36, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

42. An isolated polynucleotide which comprises the sequence of SEQ ID NO:6.

43. An isolated polynucleotide which comprises the sequence of SEQ ID NO:7.

SEQUENCE LISTING

<110> Wilson, Thomas G.
 Heinrich, Julia N.
 American Cyanamid Company

<120> RECOMBINANT BHLH-PAS/JHR POLYPEPTIDE AND ITS USE TO
 SCREEN POTENTIAL INSECTICIDES

<130> 082584/104

<140> PCT/US98/07388

<141> 1998-04-14

<150> 08/971,188

<151> 1997-11-17

<150> 08/843,205

<151> 1997-04-14

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 6234

<212> DNA

<213> St-H segment

<400> 1

aggccttgac	attgttaatc	aggtggctca	atccattata	gccatcctta	tcgaagtcga	60
tggtctcgcc	gccaaactcg	atgacctgca	aatgaatagt	gggcaaattg	tttgggatca	120
ttgaaataaa	tgactccatg	gattgagtgc	acccacctcc	ttggccctga	aggtgtccgc	180
accatggggc	actccaatga	actcgaacca	ggcccccttc	ggggggccca	gctcaccggc	240
agattgatct	ttagcttggt	gttgtctgtg	gaactggcca	gcaaagtgga	tcccgcgacg	300
ctctccacgc	gaaccattat	gctcacgggt	tggccggaaa	actgcttcag	catgccgccc	360
ttgataatcg	agcgtggatc	aaaggcatcc	ataataactc	ctcagttaat	aacgttcaaa	420
aaacagccaa	tttcagcaga	aaatgaaatg	ccgtaaacaa	gaaagagcgc	caatagtatt	480
cgagcgtgct	aatcgataat	aaaattgcat	gacgtctgct	atcgaaatta	ttcgaatttt	540
gtagcaaaaa	tatttatggg	atttattgta	acatcaaaaag	ttattacatt	attactgtgg	600
acttatgtat	tataataaga	attaataaaa	ataattttata	atagaattat	aaaaagacct	660
gatagattac	atgtattaca	acaatgttat	cgacagcgaa	caagatgttc	gaatctttct	720
gatattttgt	ccggtgtgaa	cgtgcgaatt	ttagtacgac	aaccagttac	atcgatgtat	780
cgatagtttt	tagactggcc	aatgtttatt	gttataaaaat	aatgtttaa	aataaacaat	840
taatcactta	gtataaacaa	aaataagtgc	aagcagcaag	tgcgttggtta	aaacgaccgc	900
cgccctccga	atttccttat	tgcgggcatt	aaatcgcaac	aacaacaacg	ccaccagcaa	960
cagcaacaac	aataagcagg	agattcagat	tcgcaacgca	atcaaaaacgt	aaaaaaaaaa	1020
cgaaaaataa	aaaactacaa	ggcgaaacgc	ataaataaat	agggaagcaa	ataatagtaa	1080
taataagact	aaaagcaagt	ggaaaagtac	gaaagcgaaa	agagaaaaca	tatgtacgtt	1140
gcgtgagagt	gacgtgtgtg	tgtgtgtgtc	agtgagcgaa	ggagagtggg	cgagagaggg	1200
gaggcgagca	aaaacaaaaa	caacagcaca	gcacacagca	taagcgagac	cttgaaaact	1260
ttaaaagcag	caaaaaaaac	aagacaacag	ccaaaaataa	gaaactaaaa	gctgcaaaag	1320
taataaaaaa	tatatatttag	ccgaaaaatt	tccataataa	caattctaga	agtgcggagc	1380
gtacaccctg	ttatggagag	tgacgatttt	cattttaccgc	aaggcgccaa	ttaaagggga	1440
aaatccataa	atcgaggatt	acaagtggaa	aacaaggagg	cagtaactcc	agaaaacgcc	1500
caaaaagtcc	aaaatggcag	caccagagac	gggcaacacg	ggctccacag	gatccgctgg	1560
ctcgacagga	tcgggatcgg	gatcgggatc	gggaagtggg	agctcctcag	atccagcgaa	1620
tggacgggag	gcccgtaac	ttgccgaaaa	acagcgacgg	gataagctta	atgccagcat	1680
ccaggagctg	gccaccatgg	taccacatgc	agccgaatcc	tcccgtcgcc	tggacaaaac	1740
cgccgtcctt	agattcgcca	cccatggcct	gagacttcag	tatgtctttg	gcaagtccgc	1800
ttccagacgt	cgcaagaaaa	ccggcctcaa	gggaacgggt	atgtctgcct	cacctgtcgg	1860

AMENDED SHEET

agatctaccc	aatcccagtc	tgcattctaac	ggacactcta	atgcaactgc	tggactgctg	1920
cttcctcacc	ctaacctgca	gtggccaaat	cgtttttggt	tccaccagcg	tggagcagct	1980
attgggtcac	tgtcagtcg	atttgtatgg	ccagaatcta	ctgcagatca	cgcattcccga	2040
tgatcaggat	ctgttaagac	agcagctaat	acccagggat	atagagaccc	tgttctatca	2100
gcatcagcac	caccagcagc	aggggcacaa	tccccagcag	cactccactt	ccacgtcggc	2160
ctcagcttcg	ggcagtgatc	tggaggagga	ggaaatggag	acggaggaac	accgtctggg	2220
tcggcagcag	ggagaggcgg	acgatgacga	ggatcacccg	tacaacggac	gaacacccag	2280
cccgcggaga	atggccccatt	tggcgaccat	tgatgaccga	ctacgcatgg	atcggcgctg	2340
ctttaccgtc	cgtttggcta	gggcttccac	gcgagcggag	gccacgcgtc	attacgagcg	2400
ggttaagatc	gatggctgct	ttcgtcgcag	tgactcctcc	ttaaccggag	gtgccgctgc	2460
caactatccg	attgtctccc	agctgatacg	acgctcgaga	aacaacaata	tgctggctgc	2520
cgtcgcagca	gtggcagcag	aagcggcgac	ggtgccaccc	cagcacgatg	ccattgcccc	2580
ggcggcgctg	cacgggatta	gcggcaatga	tattgtcctg	gtggccatgg	ccagggtgct	2640
gcgagaggaa	cggccgcctg	aggagacgga	gggtacagtg	ggcttgacca	tttacagaca	2700
gccagaaccc	tatcagctgg	agtaccatac	gaggcatcta	atcgacggca	gcatcatcga	2760
ctgtgatcaa	aggattggtc	tgggtggcggg	atatatgaag	gatgaggtgg	gtatatatac	2820
atcatctctc	tgaactgctt	acgacaacta	atcgtgtact	ctccactcga	aacagggtgcg	2880
caaccttagt	cccttctggt	tcatgcacct	ggacgacggt	cgtcgggtga	ttgtggccct	2940
tcgacaaatg	tacgattgca	acagtgacta	tggcgagagc	tgctaccgtc	tgctgtcccg	3000
caacggggcg	ttcattttacc	tgcacaccaa	gggattttctg	gaggtcgacc	gtggcagtaa	3060
taaggtgcat	tcctttctgt	gcgtcaacac	gctgctcgat	gaggaggcgg	gccggcaaaa	3120
ggtgcaggag	atgaaggaga	aattctcgac	aatcatcaag	gcggagatgc	ccacgcagag	3180
cagcagtcct	gatttgcccc	cctcgcaggc	accgcagcaa	cttgagagaa	ttgtcctcta	3240
tctaatagag	aacctacaga	agagtgtgga	ttcagcagag	acggttggcg	gccaggggcat	3300
ggaaagccta	atggacgatg	gctacagttc	gccagcaaat	accttaactc	tcgaggagtt	3360
agctccctcg	cccacgcccc	ccttggcctt	ggtgcgcgcg	gctccctcat	cgggtcaagag	3420
ctccatctcc	aagtcgggtga	gtgtgggtcaa	tgtgacggcg	gccagaaagt	ttcagcagga	3480
gcatcagaag	cagcgtgaac	gtgaccgtga	gcagcttaag	gagcgcacca	actccacgca	3540
gggcgtgatc	cggcaactga	gcagctgcct	aagcagggcg	gaaacggcat	cctgtatcct	3600
atcaccagcc	agtagcttga	gtgccagcga	agcaccggac	acgcccgatc	cgcacagcaa	3660
cacatcaccg	ccaccgtcgc	tccacacacg	tcccagtgtc	ctgcatcgaa	ccctgaccag	3720
cacgctgcga	tgacgggctg	atggaacctg	gtttgccttc	taattgggtg	tgtggaaatg	3780
gacgtaattg	gtagctcacg	tgcacacaaa	cgaattagta	tcggtaatat	aatcctggcc	3840
aatcgcaatg	tgaaaaccca	aaatgtatca	gaaaaaaaac	gagcattatt	caaatagttt	3900
aaaaattcag	ccaaaaaact	taaatacgaa	aaaaaagagc	gtgggttgaa	gaaccttttg	3960
ttttcatatt	cacattttcca	agctttgagc	aatcaaacia	ttttaatttt	cagtatacac	4020
atatgtataa	tgagttggct	ttacaaaagc	tattaacaaa	tcaagcaatt	gtgtaattta	4080
atatgagact	ttccgtgatt	tttgctttct	acgtactttt	cgacttcaat	tgatctatag	4140
ggtttccgta	ttaaaaacga	aattaacgtg	gtttcatttg	atgaaaatgc	aatatgagct	4200
cgcattttatt	ttgatattat	gacagtaata	atgatctgat	cacgataatc	gtttttctcaa	4260
aacataagcg	atacattttg	ggtacatttg	gccattactg	tttctgtgtg	tgatttcggg	4320
ataaaatagt	agtttgatta	catgtttatat	tgatgaatgg	cgatcgggtg	gtgctgctaa	4380
atgcgttcca	ttatcaataa	ttttcgttat	gtaattacgt	ttaatttgta	aatatgtatg	4440
agtgcgagcg	tgagtgaagt	tgtgatcgtg	tcagcatggg	tgtgaatgaa	cattagatca	4500
gtgctcggat	ttgggttttag	ttgaaattta	aaccccatth	ccccgatttc	ccagttatca	4560
ccttccgccc	caaaacacca	ttgtaaaaag	agtacaaaaa	aaaaaaraaa	agaaaataga	4620
aaaacaaaca	aacaattata	tattttatttc	gccctaagtc	tagaacgtgc	taaacacaac	4680
tcattaatag	ttaaacaaac	ggatgttgca	atcgatggaa	attaaacgct	cgtttttagt	4740
tttgccgtct	cgtcgaaga	aagaaagagg	actactacat	atgtacagtc	aaactaatcc	4800
aagtcaaact	cttcagctctc	agaattggag	actttattaa	aggtttttta	ttttatgaag	4860
aatagcataf	tattttttata	tatatatat	tatgtatata	tatttatatc	acaaatctcc	4920
ttcgatatcc	ctttgtaatc	tataaaaaaca	cttccaggcg	cagctttatt	tttcaacagt	4980
tttaattttg	ggaactttac	aaagcatata	agcatacccc	aaatccatat	ccttataaac	5040
tttgtagtta	ttacaaatgt	gttcaaaaatt	aaaaaaaana	aagtttgtca	tccaaaatcc	5100
aatccgctaa	atacaatata	atcatttttaa	ttgatctatg	ttacacttct	ataatgtcta	5160
ctggacaaaa	tatgattaag	ttgaaatttc	aaagtgtttt	tgaagtgtgt	actaacgaag	5220
tttggtctga	gttcaatact	cacagaaagg	gagcagagaca	tattcccatc	tcgctccgac	5280
ctgttatcaa	agcctttgccc	attgtccttg	gcgttgccgt	cttatcaccg	gcgtatcgga	5340
gggaatatat	gatttttttt	tcggcccaagt	ggttctagt	gtaaatatga	agcgggtgggt	5400
ggtttccggg	ggtttggggg	aaccgcgggt	ggtgatgggc	gcagagaagg	cgggaagcgg	5460
gggggaacac	gttttcgttat	tttttggttt	atagcgaaat	tcctctagct	ataaatgtat	5520

```

gcatacatat atgctattaa cttttcggtt agctcaattt tttgtttgta tttttaatta 5580
taactcggtt tgtctagtgt gtaattaaat taaaagtcca atgctaattc cccagcgaat 5640
cggtcagtggt ttgttcaaac gagttgtgct ctttaaacac ttttggctta tcctttcatt 5700
taatttttgt ttgttttcct tgcgttggtta tatgtccaaa taaaaatgaa agtttgaatt 5760
gttttttttt agtaatttag ttttaactgt aatgtcaaat gtcgagaggt atactctgta 5820
taagaataat aatgtgtaat gtaattttta gaacttgcta atctctagca attaaaacat 5880
agcctgtaat taacaataat taattataat aaccagtaac agttcatgca aatgaaacct 5940
taataaataa taaattatat aaaagaagat ggaagtgttt tcaatcaatg aagttacttc 6000
ctattttcag gagttggaat gttacacttt tttataagct gatttgaaat gcgcgccaca 6060
ttatatctgc cttgcgcgca cgcattgcag ccgaataacg gcgaattaac tcccctcaga 6120
ggtgagtttg aactatcgat tataatcgat tgcattcgga aacaaaaaac accttgagtt 6180
tggtcagatc ggttttgcgc gggataaata ataaaatatt aaatgttttc tttg 6234

```

<210> 2

<211> 3011

<212> DNA

<213> Met-JHR genomic DNA

<400> 2

```

ccaaaaataa gaaactaaaa gctgcaaaaag taataaaaaa tatatttttag ccgaaaaaatt 60
tcataaataa caattctaga agtgcgagag gtacaccctg ttatggagag tgacgatttt 120
catttaccgc aaggcgccaa ttaaagggga aaatccataa atcgaggatt acaagtggaa 180
aacaaggagg cagtaactcc agaaaacgcc caaaaagtcc aaaatggcag caccagagac 240
gggcaacacg ggctccacag gatccgctgg ctgcacagga tcgggatcgg gatcgggatc 300
gggaagtggg agctcctcag atccagcgaa tggacgggag gcccgtaacc ttgccgaaaa 360
acagcgacgg gataagctta atgccagcat ccaggagctg gccaccatgg taccacatgc 420
agccgaatcc tcccgctgcc tggacaaaac cgccgtcctt agattcgcca cccatggcct 480
gagacttcag tatgtctttg gcaagtccgc ttccagacgt cgcaagaaaa ccggcctcaa 540
gggaacgggt atgtctgcct cacctgtcgg agatctaccc aatcccagtc tgcactaac 600
ggacactcta atgcaactgc tggactgctg ctctctcacc ctaacctgca gtggccaaat 660
cgtttttggt tccaccagcg tggagcagct attgggtcac tgtcagtcgg atttgtatgg 720
ccagaatcta ctgcagatca cgcattccga tgatcaggat ctgttaagac agcagctaat 780
accaggggat atagagaccc tgttctatca gcatcagcac caccagcagc aggggcacaa 840
tccccagcag cactccactt ccacgtcggc ctcarcttcg ggcagtgatc tggaggagga 900
ggaaatggag acggaggaac accgtctggg tcggcagcag ggagaggcgg acgatgacga 960
ggatcacccg tacaaccgac gaacacccag cccgcggaga atggcccat tggcgaccat 1020
tgatgaccga ctacgcatgg atcggcgtg ctttaccgtc cgcttggcta gggcttcac 1080
gcgagcggag gccacgcgtc attacgagcg ggttaagatc gatggctgct ttcgtcgcag 1140
tgactcctcc ttaaccggag gtgccgctgc caactatccg attgtctccc agctgatacg 1200
acgctcgaga aacaacaata tgctggctgc tgcgtcagca gtggcagcag aagcggcgac 1260
ggtgcgcgcc cagcacgatg ccattgccc aagcggcgctg cacgggatta gcggcaatga 1320
tattgtcctg gtggccatgg ccagggtgct gcgagaggaa cggccgctg aggagacgga 1380
gggtacagtg ggcttgacca ttacagaca gccagaaccc tatcagttgg agtaccatac 1440
gaggcattcta atcgacggca gcatcatcga ctgtgatcaa aggattggtc tgggtggcgg 1500
atatatgaag gatgaggtgg gtatatatac atcatctctc tgaactgctt acgacaacta 1560
atcgtgtact ctccactcga aacaggtgcg caaccttagt cccttctgtt tcatgcacct 1620
ggacgacgtt cgctgggtga ttgtggccct tcgacaaatg tacgattgca acagtgacta 1680
cggcgagagc tgctaccgtc tgctgtcccg caacgggcgc ttcatttacc tgcacaccaa 1740
gggattttct gaggtcgacc gtggcagtaa taagggtgat tcctttctgt gcgtcaacac 1800
gctgctcgat gaggaggcgg gccggcaaaa ggtgcaggag atgaaggaga aattctcgac 1860
aatcatcaag gcggagatgc ccacgcagag cagcagtcct gatttgcccg cctcgcaggc 1920
accgcagcaa cttgagagaa ttgtcctcta tetaatagag aacctacaga agagtgtgga 1980
ttcagcagag acggttggcg gccagggcat ggaaagccta atggacgatg gctacagttc 2040
gccagcaaat accttaactc tcgaggagtt agctccctcg cccacgcccg ccttggcctt 2100
ggtgcgcgcc gctccctcat cggtaagag ctccatctcc aagtcggtga gtgtgggtcaa 2160
tgtgacggcg gccagaaagt ttcagcagga gcatcagaag cagcgtgaac gtgaccgtga 2220
gcagcttaag gagcgcacca actccacgca gggcgtgatc cggcaactga gcagctgcct 2280
aagcagggcg gaaacggcat cctgtatcct atcaccagcc agtagcttga gtgccagcga 2340
agcaccggac acgcccgatc cgcacagcaa cacatcaccg ccaccgtcgc tccacacacg 2400
tcccagtgct ctgcatcgaa ccctgaccag cacgctgcga tgacgggctg atggaacctg 2460
gtttgccttc taattgggtg tgtggaaatg gacgtaattg gtagctcacg tgcccacaaa 2520

```


cgaattagta	tccgcaatat	aatcctggcc	aatcgcaatg	tgaaaaccca	aaatgtatca	2580
gaaaaaaaaac	gagcattatt	caaatagttt	aaaaattcag	ccaaaaaact	taaaaacgaa	2640
aaaaaagagc	gtgggttgaa	gaaccttttg	ttttcatatt	cacatttcca	agctttgagc	2700
aatcaaacaa	ttttaatttt	cagtatacac	atatgtataa	tgagttggct	ttacaaaagc	2760
tattaacaaa	tcaagcaatt	gtgtaattta	atatgagact	ttccgtgatt	tttgctttct	2820
acgtactttt	cgacttcaat	tgatctatag	ggtttccgta	ttaaaaacga	aattaacgtg	2880
gtttcatttg	atgaaaatgc	aatatgagct	cgcatthatt	ttgatattat	gacagtaata	2940
atgatctgat	cacgataatc	gttttctcaa	aacataagcg	atacattttg	ggtacatttg	3000
gccattactg	t					3011

<210> 3

<211> 3282

<212> DNA

<213> Met-JHR cDNA

<400> 3

aaataagaaa	ctaaaagctg	caaaagtaat	aaaaaatata	ttttagccga	aaaatttcca	60
taataacaat	tctagaagtg	cggagcgtac	accctgttat	ggagagtgc	gattttcatt	120
taccgcaagg	cgccaattaa	aggggaaaat	ccataaatcg	aggattacaa	gtggaaaaca	180
aggaggcagt	aactccagaa	aacgcccaaa	aagtccaaaa	tggcagcacc	agagacgggc	240
aacacgggct	ccacaggatc	cgtctggctcg	acaggatcgg	gatcgggatc	gggatcggga	300
agtgggagct	cctcagatcc	agcgaatgga	cgggaggccc	gtaaccttgc	cgaaaaacag	360
cgacggggata	agcttaatgc	cagcatccag	gagctggcta	ccatgggtacc	acatgcagcc	420
gaatcctccc	gtcgcctgga	caaaaccgcc	gtcctcagat	ttgccaccca	tggcctgaga	480
cttcagtatg	tctttggcaa	gtccgcttcc	agacgtcgca	agaaamccgg	cctcaaggga	540
acgggtatgt	ctgcctcacc	tgtcggagat	ctaccaatc	ccagtctgca	tctaaccggac	600
actctaattg	aactgctgga	ctgctgcttc	ctcaccctaa	cctgcagtgg	ccaatcgtt	660
ttgggtatcca	ccagcgtgga	gcagctattg	ggcactgtc	agtccgattt	gtatggccag	720
aatctactgc	agatcacgca	tcccgatgat	caggatctgt	taagacagca	gctaataccc	780
agggatatag	agaccctggt	ctatcagcat	cagcaccacc	agcagcaggg	gcacaatccc	840
cagcagcact	ccacttccac	gtcggcctca	gcttcgggca	gtgatctgga	ggaggaggaa	900
atggagacgg	aggaacaccg	tctgggtcgg	cagcagggag	aggcggacga	tgacgaggat	960
cacccgta	accgacgaac	acccagcccc	cggagaatgg	cccatttggc	gaccattgat	1020
gaccgactac	gcatggattg	gcgctgcttt	accgtccgct	tggctagggc	ttccacgcga	1080
gcggaggcca	cgcgtcatta	cgagcgggtt	aagatcgatg	gctgctttcg	tgcagtgac	1140
tcctccttaa	ccggagggtgc	cgctgccaac	tatccgattg	tctcccagct	gatacgacgc	1200
tcgagaaaca	acaatatgct	ggctgccgct	gcagcagtgg	cagcagaagc	ggcgacgggtg	1260
ccaccccagc	acgatgccat	tgcccaggcg	gcgctgcacg	ggattagcgg	caatgatatt	1320
gtcctggtgg	ccatggccag	gggtgctgcga	gagggaacggc	cgcctgagga	gacggagggt	1380
acagtgggct	tgaccattta	cagacagcca	gaaccctatc	agctggagta	ccatacgagg	1440
catctaattc	acggcagcat	catcgactgt	gatcaaagga	ttgggtctgg	ggcgggatat	1500
atgaaggatg	aggtgcgcaa	ccttagtccc	ttctgtttca	tgcacctgga	cgacgttcgc	1560
tgggtgattg	tggcccttcg	acaaatgtac	gattgcaaca	gtgactatgg	cgagagctgc	1620
taccgtctgc	tgtcccgcga	cgggcgcttc	atttacctgc	acaccaaggg	atttctggag	1680
gtcgaccgtg	gcagtaataa	gggtgcattcc	tttctgtgcg	tcaacacgct	gctcgatgag	1740
gaggcggggc	ggcaaaagg	gcaggagatg	aaggagaaat	tctcgacaat	catcaaggcg	1800
gagatgccca	cgcagagcag	cagtcccgat	ttgcccgcct	cgcaggcacc	gcagcaactt	1860
gagagaattg	tcctctatct	aatagagaac	ctacagaaga	gtgtggattc	agcagagacg	1920
gttggcgggc	agggcatgga	aagcctaatt	gacgatggct	acagttcgcc	agcaaatacc	1980
ttactctctg	aggagttagc	tccctcgccc	acgcccgcct	tggccttggg	gccgccggct	2040
ccctcatcgg	tcaagagctc	catctccaag	tcgggtgagt	tgggtcaatgt	gacggcggcc	2100
agaaagtthc	agcaggagca	tcagaagcag	cgtgaacgtg	accgtgagca	gcttaaggag	2160
cgcaccaact	ccacgcaggg	cgtgatccgg	caactgagca	gctgcctaag	cgaggcggaa	2220
acggcatcct	gtatcctatc	accagccagt	agcttgagt	ccagcgaagc	accggacacg	2280
cccgatccgc	acagcaacac	atcaccgcca	cgtcgctcc	acacacgtcc	cagtgtcctg	2340
catcgaaccc	tgaccagcac	gctgcgatga	cgggctgatg	gaacctgggt	tgccttctaa	2400
ttgggtgtgt	ggaaatggac	gtaattggta	gctcacgtgc	ccacaaacga	attagtatcg	2460
gtaatatata	cctggccaat	cgcaatgtga	aaacccaaaa	tgtatcagaa	aaaaaacgag	2520
cattattcaa	atagttttaa	aattcagcca	aaaaacttaa	aaacgaaaaa	aaagagcgtg	2580
ggttgaagaa	ccttttgttt	tcatattcac	atttccaagc	tttgagcaat	caaacaattt	2640
taattttcag	tatacacata	tgtataatga	gttggcttta	caaaagctat	taacaaatca	2700

```

agcaattgtg taatttaata tgagactttc cgtgattttt gctttctacg tacttttcga 2760
cttcaattga tctatagggt ttccgtatta aaaacgaaat taacgtgggt tcatttgatg 2820
aaaatgcaat atgagctcgc atttattttg atattatgac agtaataatg atctgatcac 2880
gataatcgtt ttctcaaaac ataagcgata cattttgggt acatttggcc attactgttt 2940
ctgtgtgtga ttctcggtata aaatagtagt ttgattacat gttatattga tgaatggcga 3000
tcgggtgggtg ctgctaaatg cgttccatta tcaataattt tcgttatgta attacgttta 3060
atttgtaaat atgtatgagt gcgagcgtga gtgagtttgt gatcgtgtca gcatgggtgt 3120
gaatgaacat tagatcagt ctcggatttg gtttttagttg aaatttaaac cccatttccc 3180
cgatttccca gttatcacct tccgccccaa aacaccattg taaaaagagt acaaaaaaaaa 3240
aaagaaaaga aaatagaaaa acaaaaaaaaa aaaaaaaaaa aa 3282

```

<210> 4
 <211> 737
 <212> PRT
 <213> Met-JHR

<220>
 <223> Xaa at position 218 may be Thr or Pro

<400> 4
 Met Ala Ala Pro Glu Thr Gly Asn Thr Gly Ser Thr Gly Ser Ala Gly
 1 5 10 15
 Ser Thr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ser Ser
 20 25 30
 Asp Pro Ala Asn Gly Arg Glu Ala Arg Asn Leu Ala Glu Lys Gln Arg
 35 40 45
 Arg Asp Lys Leu Asn Ala Ser Ile Gln Glu Leu Ala Thr Met Val Pro
 50 55 60
 His Ala Ala Glu Ser Ser Arg Arg Leu Asp Lys Thr Ala Val Leu Arg
 65 70 75 80
 Phe Ala Thr His Gly Leu Arg Leu Gln Tyr Val Phe Gly Lys Ser Ala
 85 90 95
 Ser Arg Arg Arg Lys Lys Thr Gly Leu Lys Gly Thr Gly Met Ser Ala
 100 105 110
 Ser Pro Val Gly Asp Leu Pro Asn Pro Ser Leu His Leu Thr Asp Thr
 115 120 125
 Leu Met Gln Leu Leu Asp Cys Cys Phe Leu Thr Leu Thr Cys Ser Gly
 130 135 140
 Gln Ile Val Leu Val Ser Thr Ser Val Glu Gln Leu Leu Gly His Cys
 145 150 155 160
 Gln Ser Asp Leu Tyr Gly Gln Asn Leu Leu Gln Ile Thr His Pro Asp
 165 170 175
 Asp Gln Asp Leu Leu Arg Gln Gln Leu Ile Pro Arg Asp Ile Glu Thr
 180 185 190
 Leu Phe Tyr Gln His Gln His His Gln Gln Gln Gly His Asn Pro Gln
 195 200 205
 Gln His Ser Thr Ser Thr Ser Ala Ser Xaa Ser Gly Ser Asp Leu Glu
 210 215 220

AMENDED SHEET

Glu	Glu	Glu	Met	Glu	Thr	Glu	Glu	His	Arg	Leu	Gly	Arg	Gln	Gln	Gly	225	230	235	240
Glu	Ala	Asp	Asp	Asp	Glu	Asp	His	Pro	Tyr	Asn	Arg	Arg	Thr	Pro	Ser	245	250	255	
Pro	Arg	Arg	Met	Ala	His	Leu	Ala	Thr	Ile	Asp	Asp	Arg	Leu	Arg	Met	260	265	270	
Asp	Arg	Arg	Cys	Phe	Thr	Val	Arg	Leu	Ala	Arg	Ala	Ser	Thr	Arg	Ala	275	280	285	
Glu	Ala	Thr	Arg	His	Tyr	Glu	Arg	Val	Lys	Ile	Asp	Gly	Cys	Phe	Arg	290	295	300	
Arg	Ser	Asp	Ser	Ser	Leu	Thr	Gly	Gly	Ala	Ala	Ala	Asn	Tyr	Pro	Ile	305	310	315	320
Val	Ser	Gln	Leu	Ile	Arg	Arg	Ser	Arg	Asn	Asn	Asn	Met	Leu	Ala	Ala	325	330	335	
Ala	Ala	Ala	Val	Ala	Ala	Glu	Ala	Ala	Thr	Val	Pro	Pro	Gln	His	Asp	340	345	350	
Ala	Ile	Ala	Gln	Ala	Ala	Leu	His	Gly	Ile	Ser	Gly	Asn	Asp	Ile	Val	355	360	365	
Leu	Val	Ala	Met	Ala	Arg	Val	Leu	Arg	Glu	Glu	Arg	Pro	Pro	Glu	Glu	370	375	380	
Thr	Glu	Gly	Thr	Val	Gly	Leu	Thr	Ile	Tyr	Arg	Gln	Pro	Glu	Pro	Tyr	385	390	395	400
Gln	Leu	Glu	Tyr	His	Thr	Arg	His	Leu	Ile	Asp	Gly	Ser	Ile	Ile	Asp	405	410	415	
Cys	Asp	Gln	Arg	Ile	Gly	Leu	Val	Ala	Gly	Tyr	Met	Lys	Asp	Glu	Val	420	425	430	
Gly	Ile	Leu	Thr	Ser	Ser	Leu	Thr	Ala	Tyr	Asp	Asn	Ser	Cys	Thr	Leu	435	440	445	
His	Ser	Lys	Gln	Val	Arg	Asn	Leu	Ser	Pro	Phe	Cys	Phe	Met	His	Leu	450	455	460	
Asp	Asp	Val	Arg	Trp	Val	Ile	Val	Ala	Leu	Arg	Gln	Met	Tyr	Asp	Cys	465	470	475	480
Asn	Ser	Asp	Tyr	Gly	Glu	Ser	Cys	Tyr	Arg	Leu	Leu	Ser	Arg	Asn	Gly	485	490	495	
Arg	Phe	Ile	Tyr	Leu	His	Thr	Lys	Gly	Phe	Leu	Glu	Val	Asp	Arg	Gly	500	505	510	
Ser	Asn	Lys	Val	His	Ser	Phe	Leu	Cys	Val	Asn	Thr	Leu	Leu	Asp	Glu	515	520	525	
Glu	Ala	Gly	Arg	Gln	Lys	Val	Gln	Glu	Met	Lys	Glu	Lys	Phe	Ser	Thr	530	535	540	

AMENDED SHEET

Ile Ile Lys Ala Glu Met Pro Thr Gln Ser Ser Ser Pro Asp Leu Pro
545 550 555 560

Ala Ser Gln Ala Pro Gln Gln Leu Glu Arg Ile Val Leu Tyr Leu Ile
565 570 575

Glu Asn Leu Gln Lys Ser Val Asp Ser Ala Glu Thr Val Gly Gly Gln
580 585 590

Gly Met Glu Ser Leu Met Asp Asp Gly Tyr Ser Ser Pro Ala Asn Thr
595 600 605

Leu Thr Leu Glu Glu Leu Ala Pro Ser Pro Thr Pro Ala Leu Ala Leu
610 615 620

Val Pro Pro Ala Pro Ser Ser Val Lys Ser Ser Ile Ser Lys Ser Val
625 630 635 640

Ser Val Val Asn Val Thr Ala Ala Arg Lys Phe Gln Gln Glu His Gln
645 650 655

Lys Gln Arg Glu Arg Asp Arg Glu Gln Leu Lys Glu Arg Thr Asn Ser
660 665 670

Thr Gln Gly Val Ile Arg Gln Leu Ser Ser Cys Leu Ser Glu Ala Glu
675 680 685

Thr Ala Ser Cys Ile Leu Ser Pro Ala Ser Ser Leu Ser Ala Ser Glu
690 695 700

Ala Pro Asp Thr Pro Asp Pro His Ser Asn Thr Ser Pro Pro Pro Ser
705 710 715 720

Leu His Thr Arg Pro Ser Val Leu His Arg Thr Leu Thr Ser Thr Leu
725 730 735

Arg

<210> 5
<211> 716
<212> PRT
<213> Met-JHR

<220>
<223> Xaa at position 103 may be Gly or Arg

<400> 5
Met Ala Ala Pro Glu Thr Gly Asn Thr Gly Ser Thr Gly Ser Ala Gly
1 5 10 15

Ser Thr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ser Ser
20 25 30

Asp Pro Ala Asn Gly Arg Glu Ala Arg Asn Leu Ala Glu Lys Gln Arg
35 40 45

Arg Asp Lys Leu Asn Ala Ser Ile Gln Glu Leu Ala Thr Met Val Pro
50 55 60

AMENDED SHEET

PCTAUS 98/07388
IPEAUS 11 MAY 1999

His	Ala	Ala	Glu	Ser	Ser	Arg	Arg	Leu	Asp	Lys	Thr	Ala	Val	Leu	Arg	
65					70					75					80	
Phe	Ala	Thr	His	Gly	Leu	Arg	Leu	Gln	Tyr	Val	Phe	Gly	Lys	Ser	Ala	
				85					90					95		
Ser	Arg	Arg	Arg	Lys	Lys	Xaa	Gly	Leu	Lys	Gly	Thr	Gly	Met	Ser	Ala	
				100				105					110			
Ser	Pro	Val	Gly	Asp	Leu	Pro	Asn	Pro	Ser	Leu	His	Leu	Thr	Asp	Thr	
		115					120					125				
Leu	Met	Gln	Leu	Leu	Asp	Cys	Cys	Phe	Leu	Thr	Leu	Thr	Cys	Ser	Gly	
	130					135						140				
Gln	Ile	Val	Leu	Val	Ser	Thr	Ser	Val	Glu	Gln	Leu	Leu	Gly	His	Cys	
145					150					155					160	
Gln	Ser	Asp	Leu	Tyr	Gly	Gln	Asn	Leu	Leu	Gln	Ile	Thr	His	Pro	Asp	
				165					170					175		
Asp	Gln	Asp	Leu	Leu	Arg	Gln	Gln	Leu	Ile	Pro	Arg	Asp	Ile	Glu	Thr	
			180					185					190			
Leu	Phe	Tyr	Gln	His	Gln	His	His	Gln	Gln	Gln	Gly	His	Asn	Pro	Gln	
		195				200						205				
Gln	His	Ser	Thr	Ser	Thr	Ser	Ala	Ser	Ala	Ser	Gly	Ser	Asp	Leu	Glu	
	210					215					220					
Glu	Glu	Glu	Met	Glu	Thr	Glu	Glu	His	Arg	Leu	Gly	Arg	Gln	Gln	Gly	
225					230					235					240	
Glu	Ala	Asp	Asp	Asp	Glu	Asp	His	Pro	Tyr	Asn	Arg	Arg	Thr	Pro	Ser	
				245					250					255		
Pro	Arg	Arg	Met	Ala	His	Leu	Ala	Thr	Ile	Asp	Asp	Arg	Leu	Arg	Met	
			260					265					270			
Asp	Trp	Arg	Cys	Phe	Thr	Val	Arg	Leu	Ala	Arg	Ala	Ser	Thr	Arg	Ala	
	275						280					285				
Glu	Ala	Thr	Arg	His	Tyr	Glu	Arg	Val	Lys	Ile	Asp	Gly	Cys	Phe	Arg	
	290					295					300					
Arg	Ser	Asp	Ser	Ser	Leu	Thr	Gly	Gly	Ala	Ala	Ala	Asn	Tyr	Pro	Ile	
305					310					315					320	
Val	Ser	Gln	Leu	Ile	Arg	Arg	Ser	Arg	Asn	Asn	Asn	Met	Leu	Ala	Ala	
				325					330					335		
Ala	Ala	Ala	Val	Ala	Ala	Glu	Ala	Ala	Thr	Val	Pro	Pro	Gln	His	Asp	
			340					345					350			
Ala	Ile	Ala	Gln	Ala	Ala	Leu	His	Gly	Ile	Ser	Gly	Asn	Asp	Ile	Val	
	355					360						365				
Leu	Val	Ala	Met	Ala	Arg	Val	Leu	Arg	Glu	Glu	Arg	Pro	Pro	Glu	Glu	
	370					375					380					

AMENDED SHEET

Thr Glu Gly Thr Val Gly Leu Thr Ile Tyr Arg Gln Pro Glu Pro Tyr
 385 390 395 400
 Gln Leu Glu Tyr His Thr Arg His Leu Ile Asp Gly Ser Ile Ile Asp
 405 410 415
 Cys Asp Gln Arg Ile Gly Leu Val Ala Gly Tyr Met Lys Asp Glu Val
 420 425 430
 Arg Asn Leu Ser Pro Phe Cys Phe Met His Leu Asp Asp Val Arg Trp
 435 440 445
 Val Ile Val Ala Leu Arg Gln Met Tyr Asp Cys Asn Ser Asp Tyr Gly
 450 455 460
 Glu Ser Cys Tyr Arg Leu Leu Ser Arg Asn Gly Arg Phe Ile Tyr Leu
 465 470 475 480
 His Thr Lys Gly Phe Leu Glu Val Asp Arg Gly Ser Asn Lys Val His
 485 490 495
 Ser Phe Leu Cys Val Asn Thr Leu Leu Asp Glu Glu Ala Gly Arg Gln
 500 505 510
 Lys Val Gln Glu Met Lys Glu Lys Phe Ser Thr Ile Ile Lys Ala Glu
 515 520 525
 Met Pro Thr Gln Ser Ser Ser Pro Asp Leu Pro Ala Ser Gln Ala Pro
 530 535 540
 Gln Gln Leu Glu Arg Ile Val Leu Tyr Leu Ile Glu Asn Leu Gln Lys
 545 550 555 560
 Ser Val Asp Ser Ala Glu Thr Val Gly Gly Gln Gly Met Glu Ser Leu
 565 570 575
 Met Asp Asp Gly Tyr Ser Ser Pro Ala Asn Thr Leu Thr Leu Glu Glu
 580 585 590
 Leu Ala Pro Ser Pro Thr Pro Ala Leu Ala Leu Val Pro Pro Ala Pro
 595 600 605
 Ser Ser Val Lys Ser Ser Ile Ser Lys Ser Val Ser Val Val Asn Val
 610 615 620
 Thr Ala Ala Arg Lys Phe Gln Gln Glu His Gln Lys Gln Arg Glu Arg
 625 630 635 640
 Asp Arg Glu Gln Leu Lys Glu Arg Thr Asn Ser Thr Gln Gly Val Ile
 645 650 655
 Arg Gln Leu Ser Ser Cys Leu Ser Glu Ala Glu Thr Ala Ser Cys Ile
 660 665 670
 Leu Ser Pro Ala Ser Ser Leu Ser Ala Ser Glu Ala Pro Asp Thr Pro
 675 680 685
 Asp Pro His Ser Asn Thr Ser Pro Pro Pro Ser Leu His Thr Arg Pro
 690 695 700

AMENDED SHEET

Ser Val Leu His Arg Thr Leu Thr Ser Thr Leu Arg
705 710 715

<210> 6
<211> 250
<212> DNA
<213> D. melanogaster

<400> 6
atggcagcac cagagacggg caacacgggc tccacaggat ccgctggctc gacaggatcg 60
ggatcgggat cgggatcggg aagtgggagc tcctcagatc cagcgaatgg acgggaggcc 120
cgtaaccttg ccgaaaaaca gcgacgggat aagcttaatg ccagcatcca ggagctggct 180
accatggtac cacatgcagc cgaatcctcc cgtcgcctgg acaaaaccgc cgtccttaga 240
ttcgccaccc 250

<210> 7
<211> 232
<212> DNA
<213> D. erecta

<400> 7
cagcagacgc gggcaacacg ggcaccacag gatcagctgg gtccacagga tcgggatcgg 60
gaactgggac gtccgcagat ccagcgaatg gacgggaggc ccgcaatctt gccgagaaac 120
agcgacggga taagcttaat gccagcatcc aggagctggc taccatggta ccacatgtca 180
gccgaatcct cccgacgcct ggacaaaacc gccgtcctca gattcgccac cc 232

<210> 8
<211> 631
<212> PRT
<213> Drosophila

<400> 8
Met Asp Glu Ala Asn Ile Gln Asp Lys Glu Arg Phe Ala Ser Arg Glu
1 5 10 15
Asn His Cys Glu Ile Glu Arg Arg Arg Arg Asn Lys Met Thr Ala Tyr
20 25 30
Ile Thr Glu Leu Ser Asp Met Val Pro Thr Cys Ser Ala Leu Ala Arg
35 40 45
Lys Pro Asp Lys Leu Thr Ile Leu Arg Met Ala Val Ala His Met Lys
50 55 60
Ala Leu Arg Gly Thr Gly Asn Thr Ser Ser Asp Gly Thr Tyr Lys Pro
65 70 75 80
Ser Phe Leu Thr Asp Gln Glu Leu Lys His Leu Ile Leu Glu Ala Ala
85 90 95
Asp Gly Phe Leu Phe Val Val Ser Cys Asp Ser Gly Arg Val Ile Tyr
100 105 110
Val Ser Asp Ser Val Thr Pro Val Leu Asn Tyr Thr Gln Ser Asp Trp
115 120 125
Tyr Gly Thr Ser Leu Tyr Glu His Ile His Pro Asp Asp Arg Glu Lys
130 135 140

AMENDED SHEET

II

Ile 145	Arg	Glu	Gln	Leu	Ser 150	Thr	Gln	Glu	Ser	Gln 155	Asn	Ala	Gly	Arg	Ile 160
Leu	Asp	Leu	Lys	Ser 165	Gly	Thr	Val	Lys	Lys 170	Glu	Gly	His	Gln	Ser	Ser 175
Met	Arg	Leu	Ser 180	Met	Gly	Ala	Arg	Arg 185	Gly	Phe	Ile	Cys	Met	Arg	Val 190
Gly	Asn	Val 195	Asn	Pro	Glu	Ser	Met 200	Val	Ser	Gly	His	Leu 205	Asn	Arg	Leu
Lys	Gln 210	Arg	Asn	Ser	Leu	Gly 215	Pro	Ser	Arg	Asp	Gly 220	Thr	Asn	Tyr	Ala
Val 225	Val	His	Cys	Thr	Gly 230	Tyr	Ile	Lys	Asn	Trp 235	Pro	Pro	Thr	Asp	Met 240
Phe	Pro	Asn	Met	His 245	Met	Glu	Arg	Asp	Val 250	Asp	Asp	Met	Ser	Ser	His 255
Cys	Cys	Leu	Val 260	Ala	Ile	Gly	Arg	Leu 265	Gln	Val	Thr	Ser	Thr 270	Ala	Ala
Asn	Asp	Met 275	Ser	Gly	Ser	Asn	Asn 280	Gln	Ser	Glu	Phe	Ile 285	Thr	Arg	His
Ala 290	Met	Asp	Gly	Lys	Phe	Thr 295	Phe	Val	Asp	Gln	Arg 300	Val	Leu	Asn	Ile
Leu 305	Gly	Tyr	Thr	Pro	Thr 310	Glu	Leu	Leu	Gly	Lys 315	Ile	Cys	Tyr	Asp	Phe 320
Phe	His	Pro	Glu	Asp 325	Gln	Ser	His	Met	Lys 330	Glu	Ser	Phe	Asp	Gln	Val 335
Leu	Lys	Gln	Lys 340	Gly	Gln	Met	Phe	Ser 345	Leu	Leu	Tyr	Arg	Ala 350	Arg	Ala
Lys	Asn	Ser 355	Glu	Tyr	Tyr	Val	Trp 360	Leu	Arg	Thr	Gln	Ala 365	Tyr	Ala	Phe
Leu 370	Asn	Pro	Tyr	Thr	Asp	Glu 375	Val	Glu	Tyr	Ile	Val 380	Cys	Thr	Asn	Ser
Ser 385	Gly	Lys	Thr	Met	His 390	Gly	Ala	Pro	Leu	Asp 395	Ala	Ala	Ala	Ala	His 400
Thr	Pro	Glu	Gln 405	Val	Gln	Gln	Gln	Gln	Gln 410	Gln	Gln	Gln	Glu	Gln	His 415
Val	Tyr	Val	Gln 420	Ala	Ala	Pro	Gly	Val 425	Asp	Tyr	Ala	Arg	Arg 430	Glu	Leu
Thr	Pro	Val 435	Gly	Ser	Ala	Thr	Asn 440	Asp	Gly	Met	Tyr	Gln 445	Thr	His	Met
Leu 450	Ala	Met	Gln	Ala	Pro	Thr 455	Pro	Gln	Gln	Gln	Gln 460	Gln	Gln	Gln	Gln

AMENDED SHEET

Arg Pro Gly Ser Ala Gln Thr Thr Pro Val Gly Tyr Thr Tyr Asp Thr
 465 470 475 480
 Thr His Ser Pro Tyr Ser Ala Gly Gly Thr Ser Pro Leu Ala Lys Ile
 485 490 495
 Pro Lys Ser Gly Thr Ser Pro Thr Pro Val Ala Pro Asn Ser Trp Ala
 500 505 510
 Ala Leu Arg Pro Gln Gln Gln Gln Gln Gln Gln Pro Val Thr Glu
 515 520 525
 Gly Tyr Gln Tyr Gln Gln Thr Ser Pro Ala Arg Ser Pro Ser Gly Pro
 530 535 540
 Thr Tyr Thr Gln Leu Ser Ala Gly Asn Gly Asn Arg Gln Gln Ala Gln
 545 550 555 560
 Pro Gly Ala Tyr Gln Ala Gly Pro Pro Pro Pro Pro Asn Ala Pro Gly
 565 570 575
 Met Trp Asp Trp Gln Gln Ala Gly Gly His Pro His Pro Pro His Pro
 580 585 590
 Thr Ala His Pro His His Pro His Ala His Pro Gly Gly Pro Ala Gly
 595 600 605
 Ala Gly Gln Pro Gln Gly Gln Gly Val Leu Arg Tyr Ala Ala Asp Val
 610 615 620
 Gly Ser His Ala Asp His Val
 625 630

<210> 9
 <211> 789
 <212> PRT
 <213> human

<400> 9

Met Ala Ala Thr Thr Ala Asn Pro Glu Met Thr Ser Asp Val Pro Ser
 1 5 10 15
 Leu Gly Pro Ala Ile Ala Ser Gly Asn Ser Gly Pro Gly Ile Gln Gly
 20 25 30
 Gly Gly Ala Ile Val Gln Arg Ala Ile Lys Arg Arg Pro Gly Leu Asp
 35 40 45
 Phe Asp Asp Asp Gly Glu Gly Asn Ser Lys Phe Leu Arg Cys Asp Asp
 50 55 60
 Asp Gln Met Ser Asn Asp Lys Glu Arg Phe Ala Arg Ser Asp Asp Glu
 65 70 75 80
 Gln Ser Ser Ala Asp Lys Glu Arg Leu Ala Arg Glu Asn His Ser Glu
 85 90 95
 Ile Glu Arg Arg Arg Arg Asn Lys Met Thr Ala Tyr Ile Thr Glu Leu
 100 105 110

AMENDED SHEET

Ser	Asp	Met	Val	Pro	Thr	Cys	Ser	Ala	Leu	Ala	Arg	Lys	Pro	Asp	Lys	115	120	125
Leu	Thr	Ile	Leu	Arg	Met	Ala	Val	Ser	His	Met	Lys	Ser	Leu	Arg	Gly	130	135	140
Thr	Gly	Asn	Thr	Ser	Thr	Asp	Gly	Ser	Tyr	Lys	Pro	Ser	Phe	Leu	Thr	145	150	155
Asp	Gln	Glu	Leu	Lys	His	Leu	Ile	Leu	Glu	Ala	Ala	Asp	Gly	Phe	Leu	165	170	175
Phe	Ile	Val	Ser	Cys	Glu	Thr	Gly	Arg	Val	Val	Tyr	Val	Ser	Asp	Ser	180	185	190
Val	Thr	Pro	Val	Leu	Asn	Gln	Pro	Gln	Ser	Glu	Trp	Phe	Gly	Ser	Thr	195	200	205
Leu	Tyr	Asp	Gln	Val	His	Pro	Asp	Asp	Val	Asp	Lys	Leu	Arg	Glu	Gln	210	215	220
Leu	Ser	Thr	Ser	Glu	Asn	Ala	Leu	Thr	Gly	Arg	Ile	Leu	Asp	Leu	Lys	225	230	235
Thr	Gly	Thr	Val	Lys	Lys	Glu	Gly	Gln	Gln	Ser	Ser	Met	Arg	Met	Cys	245	250	255
Met	Gly	Ser	Arg	Arg	Ser	Phe	Ile	Cys	Arg	Met	Arg	Cys	Gly	Ser	Ser	260	265	270
Ser	Val	Asp	Pro	Val	Ser	Val	Asn	Arg	Leu	Ser	Phe	Val	Arg	Asn	Arg	275	280	285
Cys	Arg	Asn	Gly	Leu	Gly	Ser	Val	Lys	Asp	Gly	Glu	Pro	His	Phe	Val	290	295	300
Val	Val	His	Cys	Thr	Gly	Tyr	Ile	Lys	Ala	Trp	Pro	Pro	Ala	Gly	Val	305	310	315
Ser	Leu	Pro	Asp	Asp	Asp	Pro	Glu	Ala	Gly	Gln	Gly	Ser	Lys	Phe	Cys	325	330	335
Leu	Val	Ala	Ile	Gly	Arg	Leu	Gln	Val	Thr	Ser	Ser	Pro	Asn	Cys	Thr	340	345	350
Asp	Met	Ser	Asn	Val	Cys	Gln	Pro	Thr	Glu	Phe	Ile	Ser	Arg	His	Asn	355	360	365
Ile	Glu	Gly	Ile	Phe	Thr	Phe	Val	Asp	His	Arg	Cys	Val	Ala	Thr	Val	370	375	380
Gly	Tyr	Gln	Pro	Gln	Glu	Leu	Leu	Gly	Lys	Asn	Ile	Val	Glu	Phe	Cys	385	390	395
His	Pro	Glu	Asp	Gln	Gln	Leu	Leu	Arg	Asp	Ser	Phe	Gln	Gln	Val	Val	405	410	415
Lys	Leu	Lys	Gly	Gln	Val	Leu	Ser	Val	Met	Phe	Arg	Phe	Arg	Ser	Lys	420	425	430

AMENDED SHEET

Asn	Gln	Glu	Trp	Leu	Trp	Met	Arg	Thr	Ser	Ser	Phe	Thr	Phe	Gln	Asn	435	440	445
Pro	Tyr	Ser	Asp	Glu	Ile	Glu	Tyr	Ile	Ile	Cys	Thr	Asn	Thr	Asn	Val	450	455	460
Lys	Asn	Ser	Ser	Gln	Glu	Pro	Arg	Pro	Thr	Leu	Ser	Asn	Thr	Ile	Gln	465	470	475
Arg	Pro	Gln	Leu	Gly	Pro	Thr	Ala	Asn	Leu	Pro	Leu	Glu	Met	Gly	Ser	485	490	495
Gly	Gln	Leu	Ala	Pro	Arg	Gln	Gln	Gln	Gln	Thr	Glu	Leu	Asp	Met		500	505	510
Val	Pro	Gly	Arg	Asp	Gly	Leu	Ala	Ser	Tyr	Asn	His	Ser	Gln	Val	Val	515	520	525
Gln	Pro	Val	Thr	Thr	Thr	Gly	Pro	Glu	His	Ser	Lys	Pro	Leu	Glu	Lys	530	535	540
Ser	Asp	Gly	Leu	Phe	Ala	Gln	Asp	Arg	Asp	Pro	Arg	Phe	Ser	Glu	Ile	545	550	555
Tyr	His	Asn	Ile	Asn	Ala	Asp	Gln	Ser	Lys	Gly	Ile	Ser	Ser	Ser	Thr	565	570	575
Val	Pro	Ala	Thr	Gln	Gln	Leu	Phe	Ser	Gln	Gly	Asn	Thr	Phe	Pro	Pro	580	585	590
Thr	Pro	Arg	Pro	Ala	Glu	Asn	Phe	Arg	Asn	Ser	Gly	Leu	Ala	Pro	Pro	595	600	605
Val	Thr	Ile	Val	Gln	Pro	Ser	Ala	Ser	Ala	Gly	Gln	Met	Leu	Ala	Gln	610	615	620
Ile	Ser	Arg	His	Ser	Asn	Pro	Thr	Gln	Gly	Ala	Thr	Pro	Thr	Trp	Thr	625	630	635
Pro	Thr	Thr	Arg	Ser	Gly	Phe	Ser	Ala	Gln	Gln	Val	Ala	Thr	Gln	Ala	645	650	655
Thr	Ala	Lys	Thr	Arg	Thr	Ser	Gln	Phe	Gly	Val	Gly	Ser	Phe	Gln	Thr	660	665	670
Pro	Ser	Ser	Phe	Ser	Ser	Met	Ser	Leu	Pro	Gly	Ala	Pro	Thr	Ala	Ser	675	680	685
Pro	Gly	Ala	Ala	Ala	Tyr	Pro	Ser	Leu	Thr	Asn	Arg	Gly	Ser	Asn	Phe	690	695	700
Ala	Pro	Glu	Thr	Gly	Gln	Thr	Ala	Gly	Gln	Phe	Gln	Thr	Arg	Thr	Ala	705	710	715
Glu	Gly	Val	Gly	Val	Trp	Pro	Gln	Trp	Gln	Gly	Gln	Gln	Pro	His	His	725	730	735
Arg	Ser	Ser	Ser	Ser	Glu	Gln	His	Val	Gln	Gln	Pro	Pro	Ala	Gln	Gln	740	745	750

AMENDED SHEET

Pro Gly Gln Pro Glu Val Phe Gln Glu Met Leu Ser Met Leu Gly Asp
755 760 765

Gln Ser Asn Ser Tyr Asn Asn Glu Glu Phe Pro Asp Leu Thr Met Phe
770 775 780

Pro Pro Phe Ser Glu
785

<210> 10

<211> 626

<212> PRT

<213> brain and muscle ARNT-like protein a

<400> 10

Met Ala Asp Gln Arg Met Asp Ile Ser Ser Thr Ile Ser Asp Phe Met
1 5 10 15

Ser Pro Gly Pro Thr Asp Leu Leu Ser Ser Ser Leu Gly Thr Ser Gly
20 25 30

Val Asp Cys Asn Arg Lys Arg Lys Gly Ser Ser Thr Asp Tyr Gln Glu
35 40 45

Ser Met Asp Thr Asp Lys Asp Asp Pro His Gly Arg Leu Glu Tyr Thr
50 55 60

Glu His Gln Gly Arg Ile Lys Asn Ala Arg Glu Ala His Ser Gln Ile
65 70 75 80

Glu Lys Arg Arg Arg Asp Lys Met Asn Ser Phe Ile Asp Glu Leu Ala
85 90 95

Ser Leu Val Pro Thr Cys Asn Ala Met Ser Arg Lys Leu Asp Lys Leu
100 105 110

Thr Val Leu Arg Met Ala Val Gln His Met Arg Thr Leu Arg Gly Ala
115 120 125

Thr Asn Pro Tyr Thr Glu Ala Asn Tyr Lys Pro Thr Phe Leu Ser Asp
130 135 140

Asp Glu Leu Lys His Leu Ile Leu Arg Ala Ala Asp Gly Phe Leu Phe
145 150 155 160

Val Val Gly Cys Asp Arg Gly Lys Ile Leu Phe Val Ser Glu Ser Val
165 170 175

Phe Lys Ile Leu Asn Tyr Ser Gln Asn Asp Leu Ile Gly Gln Ser Leu
180 185 190

Phe Asp Tyr Leu His Pro Lys Asp Ile Ala Lys Val Lys Glu Gln Leu
195 200 205

Ser Ser Ser Asp Thr Ala Pro Arg Glu Arg Leu Ile Asp Ala Lys Thr
210 215 220

Gly Leu Pro Val Lys Thr Asp Ile Thr Pro Gly Pro Ser Arg Leu Cys
225 230 235 240

AMENDED SHEET

Ser	Gly	Ala	Arg	Arg	Ser	Phe	Phe	Cys	Arg	Met	Lys	Cys	Asn	Arg	Pro	245	250	255
Ser	Val	Lys	Val	Glu	Asp	Lys	Asp	Phe	Pro	Ser	Thr	Cys	Ser	Lys	Lys	260	265	270
Lys	Ala	Asp	Arg	Lys	Ser	Phe	Cys	Thr	Ile	His	Ser	Thr	Gly	Tyr	Leu	275	280	285
Lys	Ser	Trp	Pro	Pro	Thr	Lys	Met	Gly	Leu	Asp	Glu	Asp	Asn	Glu	Pro	290	295	300
Asp	Asn	Glu	Gly	Cys	Asn	Leu	Ser	Cys	Leu	Val	Ala	Ile	Gly	Arg	Leu	305	310	315
His	Ser	His	Val	Val	Pro	Gln	Pro	Val	Asn	Gly	Glu	Ile	Arg	Val	Lys	325	330	335
Ser	Met	Glu	Tyr	Val	Ser	Arg	His	Ala	Ile	Asp	Gly	Lys	Phe	Val	Phe	340	345	350
Val	Asp	Gln	Arg	Ala	Thr	Ala	Ile	Leu	Ala	Tyr	Leu	Pro	Gln	Glu	Leu	355	360	365
Leu	Gly	Thr	Ser	Cys	Tyr	Glu	Tyr	Phe	His	Gln	Asp	Asp	Ile	Gly	His	370	375	380
Leu	Ala	Glu	Cys	His	Arg	Gln	Val	Leu	Gln	Thr	Arg	Glu	Lys	Ile	Thr	385	390	395
Thr	Asn	Cys	Tyr	Lys	Phe	Lys	Ile	Lys	Asp	Gly	Ser	Phe	Ile	Thr	Leu	405	410	415
Arg	Ser	Arg	Trp	Phe	Ser	Phe	Met	Asn	Pro	Trp	Thr	Lys	Glu	Val	Glu	420	425	430
Tyr	Ile	Val	Ser	Thr	Asn	Thr	Val	Val	Leu	Ala	Asn	Val	Leu	Glu	Gly	435	440	445
Gly	Asp	Pro	Thr	Phe	Pro	Gln	Leu	Thr	Ala	Ser	Pro	His	Ser	Met	Asp	450	455	460
Ser	Met	Leu	Pro	Ser	Gly	Glu	Gly	Gly	Pro	Lys	Arg	Thr	His	Pro	Thr	465	470	475
Val	Pro	Gly	Ile	Pro	Gly	Gly	Thr	Arg	Ala	Gly	Ala	Gly	Lys	Ile	Gly	485	490	495
Arg	Met	Ile	Ala	Glu	Glu	Ile	Met	Glu	Ile	His	Arg	Ile	Arg	Gly	Ser	500	505	510
Ser	Pro	Ser	Ser	Cys	Gly	Ser	Ser	Pro	Leu	Asn	Ile	Thr	Ser	Thr	Pro	515	520	525
Pro	Pro	Asp	Ala	Ser	Ser	Pro	Gly	Gly	Lys	Lys	Ile	Leu	Asn	Gly	Gly	530	535	540
Thr	Pro	Asp	Ile	Pro	Ser	Ser	Gly	Leu	Leu	Ser	Gly	Gln	Ala	Gln	Glu	545	550	555

AMENDED SHEET

Asn Pro Gly Tyr Pro Tyr Ser Asp Ser Ser Ser Ile Leu Gly Glu Asn
565 570 575

Pro His Ile Gly Ile Asp Met Ile Asp Asn Asp Gln Gly Ser Ser Ser
580 585 590

Pro Ser Asn Asp Glu Ala Ala Met Ala Val Ile Met Ser Leu Leu Glu
595 600 605

Ala Asp Ala Gly Leu Gly Gly Pro Val Asp Phe Ser Asp Leu Pro Trp
610 615 620

Pro Leu
625

<210> 11
<211> 716
<212> PRT
<213> Met-JHR

<400> 11

Met Ala Ala Pro Glu Thr Gly Asn Thr Gly Ser Thr Gly Ser Ala Gly
1 5 10 15

Ser Thr Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ser Ser
20 25 30

Asp Pro Ala Asn Gly Arg Glu Ala Arg Asn Leu Ala Glu Lys Gln Arg
35 40 45

Arg Asp Lys Leu Asn Ala Ser Ile Gln Glu Leu Ala Thr Met Val Pro
50 55 60

His Ala Ala Glu Ser Ser Arg Arg Leu Asp Lys Thr Ala Val Leu Arg
65 70 75 80

Phe Ala Thr His Gly Leu Arg Leu Gln Tyr Val Phe Gly Lys Ser Ala
85 90 95

Ser Arg Arg Arg Lys Lys Pro Gly Leu Lys Gly Thr Gly Met Ser Ala
100 105 110

Ser Pro Val Gly Asp Leu Pro Asn Pro Ser Leu His Leu Thr Asp Thr
115 120 125

Leu Met Gln Leu Leu Asp Cys Cys Phe Leu Thr Leu Thr Cys Ser Gly
130 135 140

Gln Ile Val Leu Val Ser Thr Ser Val Glu Gln Leu Leu Gly His Cys
145 150 155 160

Gln Ser Asp Leu Tyr Gly Gln Asn Leu Leu Gln Ile Thr His Pro Asp
165 170 175

Asp Gln Asp Leu Leu Arg Gln Gln Leu Ile Pro Arg Asp Ile Glu Thr
180 185 190

Leu Phe Tyr Gln His Gln His His Gln Gln Gln Gly His Asn Pro Gln
195 200 205

AMENDED SHEET

Gln His Ser Thr Ser Thr Ser Ala Ser Ala Ser Gly Ser Asp Leu Glu
 210 215 220
 Glu Glu Glu Met Glu Thr Glu Glu His Arg Leu Gly Arg Gln Gln Gly
 225 230 235 240
 Glu Ala Asp Asp Asp Glu Asp His Pro Tyr Asn Arg Arg Thr Pro Ser
 245 250 255
 Pro Arg Arg Met Ala His Leu Ala Thr Ile Asp Asp Arg Leu Arg Met
 260 265 270
 Asp Trp Arg Cys Phe Thr Val Arg Leu Ala Arg Ala Ser Thr Arg Ala
 275 280 285
 Glu Ala Thr Arg His Tyr Glu Arg Val Lys Ile Asp Gly Cys Phe Arg
 290 295 300
 Arg Ser Asp Ser Ser Leu Thr Gly Gly Ala Ala Ala Asn Tyr Pro Ile
 305 310 315 320
 Val Ser Gln Leu Ile Arg Arg Ser Arg Asn Asn Asn Met Leu Ala Ala
 325 330 335
 Ala Ala Ala Val Ala Ala Glu Ala Ala Thr Val Pro Pro Gln His Asp
 340 345 350
 Ala Ile Ala Gln Ala Ala Leu His Gly Ile Ser Gly Asn Asp Ile Val
 355 360 365
 Leu Val Ala Met Ala Arg Val Leu Arg Glu Glu Arg Pro Pro Glu Glu
 370 375 380
 Thr Glu Gly Thr Val Gly Leu Thr Ile Tyr Arg Gln Pro Glu Pro Tyr
 385 390 395 400
 Gln Leu Glu Tyr His Thr Arg His Leu Ile Asp Gly Ser Ile Ile Asp
 405 410 415
 Cys Asp Gln Arg Ile Gly Leu Val Ala Gly Tyr Met Lys Asp Glu Val
 420 425 430
 Arg Asn Leu Ser Pro Phe Cys Phe Met His Leu Asp Asp Val Arg Trp
 435 440 445
 Val Ile Val Ala Leu Arg Gln Met Tyr Asp Cys Asn Ser Asp Tyr Gly
 450 455 460
 Glu Ser Cys Tyr Arg Leu Leu Ser Arg Asn Gly Arg Phe Ile Tyr Leu
 465 470 475 480
 His Thr Lys Gly Phe Leu Glu Val Asp Arg Gly Ser Asn Lys Val His
 485 490 495
 Ser Phe Leu Cys Val Asn Thr Leu Leu Asp Glu Glu Ala Gly Arg Gln
 500 505 510
 Lys Val Gln Glu Met Lys Glu Lys Phe Ser Thr Ile Ile Lys Ala Glu
 515 520 525

AMENDED SHEET

98707388
IPEA/US 11 MAY 1999

Met Pro Thr Gln Ser Ser Ser Pro Asp Leu Pro Ala Ser Gln Ala Pro
530 535 540

Gln Gln Leu Glu Arg Ile Val Leu Tyr Leu Ile Glu Asn Leu Gln Lys
545 550 555 560

Ser Val Asp Ser Ala Glu Thr Val Gly Gly Gln Gly Met Glu Ser Leu
565 570 575

Met Asp Asp Gly Tyr Ser Ser Pro Ala Asn Thr Leu Thr Leu Glu Glu
580 585 590

Leu Ala Pro Ser Pro Thr Pro Ala Leu Ala Leu Val Pro Pro Ala Pro
595 600 605

Ser Ser Val Lys Ser Ser Ile Ser Lys Ser Val Ser Val Val Asn Val
610 615 620

Thr Ala Ala Arg Lys Phe Gln Gln Glu His Gln Lys Gln Arg Glu Arg
625 630 635 640

Asp Arg Glu Gln Leu Lys Glu Arg Thr Asn Ser Thr Gln Gly Val Ile
645 650 655

Arg Gln Leu Ser Ser Cys Leu Ser Glu Ala Glu Thr Ala Ser Cys Ile
660 665 670

Leu Ser Pro Ala Ser Ser Leu Ser Ala Ser Glu Ala Pro Asp Thr Pro
675 680 685

Asp Pro His Ser Asn Thr Ser Pro Pro Pro Ser Leu His Thr Arg Pro
690 695 700

Ser Val Leu His Arg Thr Leu Thr Ser Thr Leu Arg
705 710 715

<210> 12
<211> 808
<212> PRT
<213> human

<400> 12

Met Asn Ser Ser Ser Ala Asn Ile Thr Tyr Ala Ser Arg Lys Arg Arg
1 5 10 15

Lys Pro Val Gln Lys Thr Val Lys Pro Ile Pro Ala Glu Gly Ile Lys
20 25 30

Ser Asn Pro Ser Lys Arg His Arg Asp Arg Leu Asn Thr Glu Leu Asp
35 40 45

Arg Leu Ala Ser Leu Leu Pro Phe Pro Gln Asp Val Ile Asn Lys Leu
50 55 60

Asp Lys Leu Ser Val Leu Arg Leu Ser Val Ser Tyr Leu Arg Ala Lys
65 70 75 80

Ser Phe Phe Asp Val Ala Leu Lys Ser Ser Pro Thr Glu Arg Asn Gly
85 90 95

AMENDED SHEET

Gly	Gln	Asp	Asn	Cys	Arg	Ala	Ala	Asn	Phe	Arg	Glu	Gly	Leu	Asn	Leu	
			100					105					110			
Gln	Glu	Gly	Glu	Phe	Leu	Leu	Gln	Ala	Leu	Asn	Gly	Phe	Val	Leu	Val	
		115					120					125				
Val	Thr	Thr	Asp	Ala	Leu	Val	Phe	Tyr	Ala	Ser	Ser	Thr	Ile	Gln	Asp	
	130					135					140					
Tyr	Leu	Gly	Phe	Gln	Gln	Ser	Asp	Val	Ile	His	Gln	Ser	Val	Tyr	Glu	
145					150					155					160	
Leu	Ile	His	Thr	Glu	Asp	Arg	Ala	Glu	Phe	Gln	Arg	Gln	Leu	His	Trp	
				165					170					175		
Ala	Leu	Asn	Pro	Ser	Gln	Cys	Thr	Glu	Ser	Gly	Gln	Gly	Ile	Glu	Glu	
			180					185					190			
Ala	Thr	Gly	Leu	Pro	Gln	Thr	Val	Val	Cys	Tyr	Asn	Pro	Asp	Gln	Ile	
		195					200					205				
Pro	Pro	Glu	Asn	Ser	Pro	Leu	Met	Glu	Arg	Cys	Phe	Ile	Cys	Arg	Leu	
		210				215					220					
Arg	Cys	Leu	Leu	Asp	Asn	Ser	Ser	Gly	Phe	Leu	Ala	Met	Asn	Phe	Gln	
225					230					235					240	
Gly	Lys	Leu	Lys	Tyr	Leu	His	Gly	Gln	Lys	Lys	Lys	Gly	Lys	Asp	Gly	
				245					250					255		
Ser	Ile	Leu	Pro	Pro	Gln	Leu	Ala	Leu	Phe	Ala	Ile	Ala	Thr	Pro	Leu	
			260					265					270			
Gln	Pro	Pro	Ser	Ile	Leu	Glu	Ile	Arg	Thr	Lys	Asn	Phe	Ile	Phe	Arg	
		275					280					285				
Thr	Lys	His	Lys	Leu	Asp	Phe	Thr	Pro	Ile	Gly	Cys	Asp	Ala	Lys	Gly	
	290					295					300					
Arg	Ile	Val	Leu	Gly	Tyr	Thr	Glu	Ala	Glu	Leu	Cys	Thr	Arg	Gly	Ser	
305					310					315					320	
Gly	Tyr	Gln	Phe	Ile	His	Ala	Ala	Asp	Met	Leu	Tyr	Cys	Ala	Glu	Ser	
				325					330					335		
His	Ile	Arg	Met	Ile	Lys	Thr	Gly	Glu	Ser	Gly	Met	Ile	Val	Phe	Arg	
			340					345					350			
Leu	Leu	Thr	Lys	Asn	Asn	Arg	Trp	Thr	Trp	Val	Gln	Ser	Asn	Ala	Arg	
		355					360					365				
Leu	Leu	Tyr	Lys	Asn	Gly	Arg	Pro	Asp	Tyr	Ile	Ile	Val	Thr	Gln	Arg	
	370					375					380					
Pro	Leu	Thr	Asp	Glu	Glu	Gly	Thr	Glu	His	Leu	Arg	Lys	Arg	Asn	Thr	
385					390					395					400	
Lys	Leu	Pro	Phe	Met	Phe	Thr	Thr	Gly	Glu	Ala	Val	Leu	Tyr	Glu	Ala	
				405					410					415		

AMENDED SHEET

Thr	Asn	Pro	Phe	Pro	Ala	Ile	Met	Asp	Pro	Leu	Pro	Leu	Arg	Thr	Lys	420	425	430
Asn	Gly	Thr	Ser	Gly	Lys	Asp	Ser	Ala	Thr	Thr	Ser	Thr	Leu	Ser	Lys	435	440	445
Asp	Ser	Leu	Asn	Pro	Ser	Ser	Leu	Leu	Ala	Ala	Met	Met	Gln	Gln	Asp	450	455	460
Glu	Ser	Ile	Tyr	Leu	Tyr	Pro	Ala	Ser	Ser	Thr	Ser	Ser	Thr	Ala	Pro	465	470	475
Phe	Glu	Asn	Asn	Phe	Phe	Asn	Glu	Ser	Met	Asn	Glu	Cys	Arg	Asn	Trp	485	490	495
Gln	Asp	Asn	Thr	Ala	Pro	Met	Gly	Asn	Asp	Thr	Ile	Leu	Lys	His	Glu	500	505	510
Gln	Ile	Asp	Gln	Pro	Gln	Asp	Val	Asn	Ser	Phe	Ala	Gly	Gly	His	Pro	515	520	525
Gly	Leu	Phe	Gln	Asp	Ser	Lys	Asn	Ser	Asp	Leu	Tyr	Ser	Ile	Met	Lys	530	535	540
Asn	Leu	Gly	Ile	Asp	Phe	Glu	Asp	Ile	Arg	His	Met	Gln	Asn	Glu	Lys	545	550	555
Phe	Phe	Arg	Asn	Asp	Phe	Ser	Gly	Glu	Val	Asp	Phe	Arg	Asp	Ile	Asp	565	570	575
Leu	Thr	Asp	Glu	Ile	Leu	Thr	Tyr	Val	Gln	Asp	Ser	Leu	Ser	Lys	Ser	580	585	590
Pro	Phe	Ile	Pro	Ser	Asp	Tyr	Gln	Gln	Gln	Gln	Ser	Leu	Ala	Leu	Asn	595	600	605
Ser	Ser	Cys	Met	Val	Gln	Glu	His	Leu	His	Leu	Glu	Gln	Gln	Gln	Gln	610	615	620
His	His	Gln	Lys	Gln	Val	Val	Val	Glu	Pro	Gln	Gln	Gln	Leu	Cys	Gln	625	630	635
Lys	Met	Lys	His	Met	Gln	Val	Asn	Gly	Met	Phe	Glu	Asn	Trp	Asn	Ser	645	650	655
Asn	Gln	Phe	Val	Pro	Phe	Asn	Cys	Pro	Gln	Gln	Asp	Pro	Gln	Gln	Tyr	660	665	670
Asn	Val	Phe	Thr	Asp	Leu	His	Gly	Ile	Ser	Gln	Glu	Phe	Pro	Tyr	Lys	675	680	685
Ser	Glu	Met	Asp	Ser	Met	Pro	Tyr	Thr	Gln	Asn	Phe	Ile	Ser	Cys	Asn	690	695	700
Gln	Pro	Val	Leu	Pro	Gln	His	Ser	Lys	Cys	Thr	Glu	Leu	Asp	Tyr	Pro	705	710	715
Met	Gly	Ser	Phe	Glu	Pro	Ser	Pro	Tyr	Pro	Thr	Thr	Ser	Ser	Leu	Glu	725	730	735

AMENDED SHEET

Asp Phe Val Thr Cys Leu Gln Leu Pro Glu Asn Gln Lys His Gly Leu
740 745 750

Asn Pro Gln Ser Ala Ile Ile Thr Pro Gln Thr Cys Tyr Ala Gly Ala
755 760 765

Val Ser Met Tyr Gln Cys Gln Pro Glu Pro Gln His Thr His Val Gly
770 775 780

Gln Met Gln Tyr Asn Pro Val Leu Pro Gly Gln Gln Ala Phe Leu Asn
785 790 795 800

Lys Phe Gln Asn Gly Val Phe Lys
805

<210> 13
<211> 10
<212> DNA
<213> Met-JHR cDNA

<400> 13
caaatggca

10

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: motif that
interacts with co-activators of steroid receptors

<220>
<223> Xaa may be any amino acid

<400> 14
Leu Xaa Xaa Leu Leu
1 5

and the DNA binding region of a second polypeptide, (2) DNA encoding a bHLH-PAS polypeptide and the activation domain of said second polypeptide, and (3) a reporter gene under the control of a minimal promoter driven by the response element for said second polypeptide;

(b) incubating a test compound with said host cell; and

(c) detecting the binding of the test compound with said bHLH-PAS polypeptide by monitoring expression of the reporter gene.

37. A method according to claim 32, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

38. A method according to claim 33, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

39. A method according to claim 34, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

40. A method according to claim 35, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

41. A method according to claim 36, wherein said host cell is selected from the group of an insect cell, a yeast cell, and a mammalian cell.

42. An isolated polynucleotide which comprises the sequence of SEQ ID NO:6.

43. An isolated polynucleotide which comprises the sequence of SEQ ID NO:7.